StockNYSE · US · USDHealthcare · Health Information Services
$EVH
Evolent Health, Inc.
Evolent provides specialty care management and administrative services for health plans, other risk-bearing entities and payers, supporting physicians and other healthcare providers in delivering evidence-based care. It focuses on oncology, cardiology and musculoskeletal care, with diagnostic services such as radiology and genetic testing. Its services include provider networks, clinical pathways, care management technology, quality management and support for outpatient orthopedic surgery. Evolent also offers health plan administration, pharmacy benefit management, risk management, analytics and reporting, and leadership and management services. Its technology includes CarePro, for specialty care management, and Identifi, a platform for managing data, care workflows and patient engagement. Evolent earns fees through non-capitation and capitation specialty care arrangements, recurring multi-year administrative platform and operations contracts, and some per-case services. Fees are generally fixed per member per month. It markets and sells its services to payers and providers throughout the United States. Evolent is headquartered in Arlington, Virginia.
EVH reported Q3 2026 revenue of $725.4M (51.3% YoY growth, in line with estimates) and adjusted EPS of $0.06 (in line). Adjusted EBITDA was $34.26M, beating estimates by 3.1%. The company reconfirmed full-year revenue guidance of $2.65B and raised EBITDA guidance to $132.5M. Sales volumes fell 4.2% YoY, while operating margin declined to -0.9%. EVH expanded its AI platform, Oncology care, and National payer scale, citing cost savings and margin expansion potential.
Oppenheimer kept its Outperform rating on Evolent Health and raised its price target to $7 from $6, suggesting a 54.2% upside from the Nov 5 close of $4.54, according to the firm.
Needham kept its Buy rating on Evolent Health and raised its price target to $6 from $5, a 20% increase. The new target suggests a 32.2% upside from the Nov 5 close of $4.54, according to the firm.
via TradingView
EVH sentiment & insider activity
Recent EVH coverage spans earnings, financial news and market movers.
What's driving EVH
Earnings were in line with estimates; guidance unchanged, margin pressure noted.
Evolent posted stronger-than-expected revenue and loss improvement, and announced expansion of oncology services, suggesting near‑term earnings upside.
AlphAI scores every news story that mentions EVH with an AI model for sentiment and relevance, and aggregates insider trades from Evolent Health, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
EVH reported Q3 2026 revenue of $725.4M (51.3% YoY growth, in line with estimates) and adjusted EPS of $0.06 (in line). Adjusted EBITDA was $34.26M, beating estimates by 3.1%. The company reconfirmed full-year revenue guidance of $2.65B and raised EBITDA guidance to $132.5M. Sales volumes fell 4.2% YoY, while operating margin declined to -0.9%. EVH expanded its AI platform, Oncology care, and National payer scale, citing cost savings and margin expansion potential.
Oppenheimer kept its Outperform rating on Evolent Health and raised its price target to $7 from $6, suggesting a 54.2% upside from the Nov 5 close of $4.54, according to the firm.
Needham kept its Buy rating on Evolent Health and raised its price target to $6 from $5, a 20% increase. The new target suggests a 32.2% upside from the Nov 5 close of $4.54, according to the firm.
Evolent Health reported 3Q 2026 revenue of $725.37M, up 51.3% YoY, with a net loss of $0.21 per share. Growth came from new contracts and expanded services, offset by lower membership and rate adjustments. Higher claims costs increased the medical expense ratio to 93.0%.
Evolent Health announced new and renewed contracts, including an expansion of oncology services covering about 1 million people. The company reported Q3 2026 revenue of $725.4M, a net loss of $23.6M, and adjusted EBITDA of $34.3M. CEO Seth Blackley highlighted growth from existing clients and strong performance in oncology launches, expecting AI and oncology solutions to drive future growth.
Shares of GoodRx, Evolent Health, UFP Technologies, Centene, and HCA Healthcare surged after Democrats regained majorities in Congress, easing drug pricing policy concerns. Analysts expect the biopharmaceutical sector to benefit from reduced regulatory uncertainty. UFP Technologies, up 21.5%, has seen significant volatility and strong performance, including a 51.1% year-to-date gain.
Evolent Health (EVH) reported Q2 revenue of $652.5M, up 46.9% YoY, beating estimates. Astrana Health (ASTH) reported $972.5M, up 48.5%, missing estimates. Tandem Diabetes (TNDM) reported $254.6M, up 5.8%, in line with estimates. GoodRx (GDRX) reported $200.4M, down 1.3%, beating estimates. All stocks rose post-earnings.
Evolent Health (EVH) reported Q2 2026 revenue of $652.5M versus $444.3M a year earlier, citing the Highmark contract launch. Net loss attributable to common shareholders was $28.4M. Adjusted EBITDA was $28.1M. Full-year 2026 revenue guidance was raised to $2.6B-$2.7B and adjusted EBITDA to $120M-$135M. 2027 revenue growth is expected to exceed 25%.
Evolent Health (EVH) Q2 results beat Wall Street on revenue and profitability, helped by a successful Highmark contract launch and strong customer renewals, according to management. CEO Seth Blackley said clinical engagement for new partnerships like Aetna and Highmark is above target, and automation via Auth Intelligence improved efficiency. Analysts asked about reserving, margins, oncology costs, Medicaid headwinds, and the pipeline.
Wall Street analysts issued multiple rating changes. Argus upgraded Boeing (BA) to Buy and set a $265 target; Truist upgraded Best Buy (BBY) to Buy with a $95 target; Argus upgraded Centene (CNC) to Buy with an $80 target. Other moves included UBS upgrading Jabil (JBL) to Buy, BofA downgrading AppLovin (APP) to Neutral, and Barclays downgrading Under Armour (UAA) to Underweight.